The relation between tirzepatide and adverse cardiovascular events or renal adverse events: a meta-analysis based on randomized controlled trials Authors: Lishen Liu, Jingqi Chen, Xiaoming Zhang, Sidong Zhu, Tianfu Dai, Qingping Wu, Yinchao Fang Published: 2025 ABSTRACT BackgroundThis meta-analysis aimed to evaluate the relation between tirzepatide exposure and the risk of adverse cardiovascular or renal events in participants with type 2 diabetes mellitus (T2DM) or obesity.MethodsA comprehensive search was conducted from inception until 17th September 2025 across PubMed, Web of Science, EMBASE, ScienceDirect, and ClinicalTrials.gov. Randomized controlled trials (RCTs) comparing tirzepatide with a control group (placebo or other active treatments) in participants with T2DM or obesity that reported adverse cardiovascular events (myocardial infarction (MI), coronary artery disease (CAD), heart failure (HF), and stroke) or adverse renal events (urinary tract infections, kidney stones, renal impairment, renal cell carcinoma) were included. Risk ratios (RR) with 95% confidence intervals (CI) were set to evaluate.ResultsA total of 20 RCTs involving 15,905 participants were included. Overall, no significant relation was observed between tirzepatide exposure and adverse cardiovascular events (RR = 0.83, 95%CI: 0.63–1.08, p = 0.16, I²=0%) or adverse renal events (RR = 1.22, 95%CI: 0.78–1.89, p = 0.39, I²=0%) compared with the control group. Subgroup analyses based on indication (T2DM or obesity), subtype of adverse cardiovascular events, subtype of adverse renal events, dose of tirzepatide, and type of comparator showed no significant differences between the tirzepatide and control groups.ConclusionIn participants with T2DM or obesity, no significant difference between exposure group and control group was observed in our findings. However, longer-term safety, especially in high-risk groups, cannot be ascertained due to heterogeneous outcome definitions and short follow-up durations.Trial registrationThe study was registered with PROSPERO and the ID number is CRD420251054743.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13098-025-02064-1. Introduction Type 2 diabetes mellitus (T2DM) has emerged as a critical global public health challenge. According to the latest epidemiological data, approximately 529 million individuals worldwide are affected by diabetes, with T2DM accounting for 96% of all cases [1]. The main causes of death in T2DM patients include complications such as diabetic kidney disease (DKD) and cardiovascular diseases (CVDs) [2]. Compared with non-T2DM patients, patients with T2DM have twice the risk of cardiovascular disease mortality [3]. Meanwhile, both the incidence and mortality of DKD have significantly increased. In 2019, DKD caused by type 2 diabetes (DKD-T2DM) was associated with 2.5 million incident cases, 129 million patients, 4,059,900 deaths, and 9.87 million disability-adjusted life years (DALYs) [4]. Compared to 1990, the global number of new DKD-T2DM cases in 2021 increased by 167.2%, and the patient population is projected to exceed 130 million by 2030 [5]. It is well-known that simple obesity is also a risk factor for T2DM. Currently, the global obese population has exceeded 1 billion [6]. Notably, obesity is also an independent risk factor for chronic kidney disease (CKD) and CVDs. Obesity may indirectly contribute to CKD and CVDs through mechanisms such as adipocytokine-mediated glomerular inflammation, oxidative stress, and endothelial dysfunction [7]. Glycemic control and weight regulation can delay DKD progression and mitigate complications. Recent advances in pharmacotherapy have highlighted the cardiorenal protective effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Among SGLT-2i agents, empagliflozin demonstrated a 39% reduction in renal disease incidence compared to placebo [8]. Similarly, canagliflozin treatment was associated with a 14% lower risk of cardiovascular events versus placebo in high-risk T2DM patients [9]. In the GLP-1 RA class, the LEADER trial revealed that liraglutide significantly reduced the incidence of kidney composite outcomes by 22% and lowered the risk of adverse cardiovascular events by 13%, including cardiovascular death, non-fatal myocardial infarction (MI), or stroke [10]. Tirzepatide, a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, has been approved for T2DM management and obesity-related weight control due to its potent HbA1c-lowering and weight-reducing effects [11]. Currently, a clinical trial has demonstrated that tirzepatide actually reduces death and heart failure (HF) worsening events while improving health status in obese patients (without T2DM) with HF [12]. While recent meta-analyses, including that by Kamrul-Hasan et al. [13, 14], have synthesized evidence on tirzepatide’s renal outcomes, they may not incorporate the most recent trial data or detailed subgroup. To address these limitations, this updated meta-analysis aims to provide a comprehensive evaluation by (1) assessing a broader predefined composite of cardiorenal clinical events; (2) including recent RCTs and trials involving participants with obesity but without T2DM; (3) performing more granular subgroup analyses. Materials and methods Research registration According to the Meta-analyses (PRISMA) protocol [15], this meta-analysis has been registered in the International Prospective Register of Systematic Reviews, and its registration application number is CRD420251054743. Retrieval strategy The study retrieval was conducted by two independent researchers (X. Zhang and S. Zhu). Any disagreement was resolved by consensus with a third researcher (L. Liu). From the inception of the databases until 17th September 2025, a comprehensive search was conducted across PubMed, Web of Science, EMBASE, ScienceDirect, and ClinicalTrials.gov to identify studies related to tirzepatide, renal events, and adverse cardiovascular events. The search strategy combined Medical Subject Headings (MeSH) terms and free-text terms. To minimize the risk of omitting eligible studies, the reference lists of all retrieved articles were also manually screened. The key MeSH terms included “Myocardial Infarction”, “Coronary Artery Disease”, “Heart Failure”, “Stroke”, “Urinary Tract Infections”, “Nephrolithiasis”, “Acute Kidney Injury”, and “Carcinoma, Renal Cell”. The core concepts of the search were as follows: (“tirzepatide” OR “LY3298176”) AND ((“myocardial infarction” OR “coronary artery disease” OR “heart failure” OR “stroke” “adverse cardiovascular events”) OR (“urinary tract infection” OR “nephrolithiasis” OR “kidney injury” OR “renal cancer”)). The search strategy for all databases was detailed in Supplementary Search Strategy. Data inclusion and exclusion criteria According to the principle of PICOS (participants, intervention, control, outcomes, study design), the following data will be included: (1) the subjects were participants with T2DM or obesity; (2) the intervention measure was tirzepatide; (3) the comparison measure was not using tirzepatide (other hypoglycemic drugs or placebo to treat T2DM as well as other weight-loss drugs or placebo to treat obesity); (4) the study outcomes were investigator-reported adverse events, including adverse cardiovascular events (e.g., MI, stroke) or renal adverse events (e.g., urinary tract infection (UTI), nephrolithiasis, kidney injury (KI), renal cell carcinoma); (5) the study design belonged to RCTs. The only language restriction applied was the exclusion of publications not in English. No restrictions were placed on publication status (e.g., conference abstracts, preprints) provided they were in English and met all other criteria. Data will be excluded if they: (1) study was not written in English; (2) the data was unavailable; (3) there were no outcomes of interest in study; (4) the total sample size is less than 50; (5) when the updated studies came from the same cohort, the most comprehensive or latest studies would be included preferentially. Data extraction and quality evaluation The data extraction and quality evaluation of the study were completed by two researchers (T. Dai and Q. Wu). If there were differences, they were discussed with the third researcher (J. Chen) to reach a consensus. According to the pre-designed table, the study information (clinical trial number, publication time, study design, etc.), information of participants (gender, age, therapeutic regimen, physical condition, etc.) and adverse cardiovascular events or renal adverse events were extracted. Following Cochrane guidelines, the Cochrane Collaboration Risk of Bias Tool (CCRBT) can be used to evaluate the bias risk of RCTs. Trials will be evaluated from the following seven aspects: (1) random sequence generation (selection bias); (2) allocation concealment (selection bias); (3) blinding of participants and personnel (performance bias); (4) blinding of outcome assessment (detection bias); (5) incomplete outcome data (attrition bias); (6) selective reporting (reporting bias); (7) other bias. Each aspect was classified into “low risk”, “high risk” and “unclear risk”. All studies were evaluated by researchers independently. Statistical analysis Statistical analysis was evaluated by statistical software Review Manager 5.3 (RevMan version 5.3; Oxford, UK). The subgroup analysis plan, including analyses by indication, event subtype, dose, and comparator, was pre-specified prior to data analysis. The risk ratio (RR) calculated as the effect quantity and the 95% confidence interval (95%CI) were set to evaluate the relation of tirzepatide with adverse cardiovascular events or renal adverse events. When RR < 1, the results support the intervention group. On the contrary, when RR > 1, the results support the control group. Heterogeneity among studies was assessed by chi-square test, and inconsistency index (I2) was calculated. It was generally considered that I2 ≤ 25% was no heterogeneity, 25%< I2 ≤ 50% was mild heterogeneity, 50% < I2 ≤ 75% was moderate heterogeneity, I2 > 75% was severe heterogeneity. The random effect model was used when I2 > 50%, while the fixed effect model was used when I2 ≤ 50%. In addition, to test the publication bias, the funnel plot was used. Sensitivity analysis was performed through the leave-one-out method. All statistical analyses were conducted using two-sided tests. It was considered statistically significant when p < 0.05 in two-sided test. Results Description of study retrieval Following systematic database searches, 2,406 records were identified across five electronic databases. After duplicate removal, 1,328 studies remained. Through title/abstract screening, 1,255 studies were excluded, leaving 73 for full-text assessment. During full-text evaluation, 5 studies were excluded due to small sample sizes (total N < 50), one study was excluded for single-arm design, 47 studies were excluded because they did not report interesting outcomes. Ultimately, 20 studies [16–35] met al.l eligibility criteria and were included in the meta-analysis, as shown in Fig. 1. Fig. 1Flow diagram illustrating the study selection process Flow diagram illustrating the study selection process Characteristics of study and participants Between 2019 and 2025, 20 RCTs were published, recruiting over 15,000 participants. Among these, 10,365 participants were assigned to the intervention group (tirzepatide group) and 5,540 participants to the control group. Among the studies, 13 involved participants with T2DM, while 7 focused on obese participants (without T2DM). All participants in the intervention group received tirzepatide for the treatment of T2DM or obesity. In the control group, participants with T2DM received placebo or other hypoglycemic drugs such as insulin and GLP-1 RAs, whereas obese participants received only placebo. Detailed study characteristics are presented in Table 1. Additional participant characteristics are provided in Supplementary Table 1. Table 1Characteristics of all the studies included in the meta-analysisAuthorYearClinicaltrials.gov numberIndicationTreatment regimensNumber of patientsExperimentControlExperimentControlInagaki, N.2022NCT03861052T2DMTirzepatide5 mg/10 mg/15 mgDulaglutide 0.75 mg477159Heise, T.2022NCT03951753T2DMTirzepatide15 mgPlacebo/Semaglutide 1 mg4572Frias, J. P.2019NCT03131687T2DMTirzepatide1 mg/5 mg/10 mg/15 mgPlacebo/Dulaglutide 1.5 mg211105Rosenstock, J.2021NCT03954834T2DMTirzepatide5 mg/10 mg/15 mgPlacebo363115Ludvik, B.2022NCT03882970T2DMTirzepatide5 mg/10 mg/15 mgInsulin Degludec1079365Dahl, D.2022NCT04039503T2DMTirzepatide5 mg/10 mg/15 mgPlacebo355120Del Prato, S.2022NCT03730662T2DMTirzepatide5 mg/10 mg/15 mgInsulin Glargine9971005Gao, L.2023NCT04093752T2DMTirzepatide5 mg/10 mg/15 mgDulaglutide 0.75 mg687220Frías, J. P.2022NCT03987919T2DMTirzepatide5 mg/10 mg/15 mgSemaglutide 1 mg1409469Rosenstock, J.2023NCT04537923T2DMTirzepatide5 mg/10 mg/15 mgInsulin Lispro717711Garvey, W. T.2024NCT04657003T2DMTirzepatide10 mg/15 mgPlacebo623315None2025NCT05691712T2DMTirzepatide5 mg/10 mg/15 mgPlacebo19364Billings, Lk Auid-Orcid2025NCT05564039T2DMTirzepatide15 mgDulaglutide 4.5 mg139143Jastreboff, A. M.2024NCT04184622ObesityTirzepatide5 mg/10 mg/15 mgPlacebo1896643Aronne, L. J.2024NCT04660643ObesityTirzepatidePlacebo335335Wadden, T. A.2024NCT04657016ObesityTirzepatidePlacebo287292Zhao, L.2024NCT05024032ObesityTirzepatide10 mg/15 mgPlacebo14169Kadowaki, T.2024NCT04844918ObesityTirzepatide10 mg/15 mgPlacebo15075None2024NCT04081337ObesityTirzepatide15 mgPlacebo2728Malhotra, A.2024NCT05412004ObesityTirzepatide10 mg/15 mgPlacebo234235 Table 1Characteristics of all the studies included in the meta-analysisAuthorYearClinicaltrials.gov numberIndicationTreatment regimensNumber of patientsExperimentControlExperimentControlInagaki, N.2022NCT03861052T2DMTirzepatide5 mg/10 mg/15 mgDulaglutide 0.75 mg477159Heise, T.2022NCT03951753T2DMTirzepatide15 mgPlacebo/Semaglutide 1 mg4572Frias, J. P.2019NCT03131687T2DMTirzepatide1 mg/5 mg/10 mg/15 mgPlacebo/Dulaglutide 1.5 mg211105Rosenstock, J.2021NCT03954834T2DMTirzepatide5 mg/10 mg/15 mgPlacebo363115Ludvik, B.2022NCT03882970T2DMTirzepatide5 mg/10 mg/15 mgInsulin Degludec1079365Dahl, D.2022NCT04039503T2DMTirzepatide5 mg/10 mg/15 mgPlacebo355120Del Prato, S.2022NCT03730662T2DMTirzepatide5 mg/10 mg/15 mgInsulin Glargine9971005Gao, L.2023NCT04093752T2DMTirzepatide5 mg/10 mg/15 mgDulaglutide 0.75 mg687220Frías, J. P.2022NCT03987919T2DMTirzepatide5 mg/10 mg/15 mgSemaglutide 1 mg1409469Rosenstock, J.2023NCT04537923T2DMTirzepatide5 mg/10 mg/15 mgInsulin Lispro717711Garvey, W. T.2024NCT04657003T2DMTirzepatide10 mg/15 mgPlacebo623315None2025NCT05691712T2DMTirzepatide5 mg/10 mg/15 mgPlacebo19364Billings, Lk Auid-Orcid2025NCT05564039T2DMTirzepatide15 mgDulaglutide 4.5 mg139143Jastreboff, A. M.2024NCT04184622ObesityTirzepatide5 mg/10 mg/15 mgPlacebo1896643Aronne, L. J.2024NCT04660643ObesityTirzepatidePlacebo335335Wadden, T. A.2024NCT04657016ObesityTirzepatidePlacebo287292Zhao, L.2024NCT05024032ObesityTirzepatide10 mg/15 mgPlacebo14169Kadowaki, T.2024NCT04844918ObesityTirzepatide10 mg/15 mgPlacebo15075None2024NCT04081337ObesityTirzepatide15 mgPlacebo2728Malhotra, A.2024NCT05412004ObesityTirzepatide10 mg/15 mgPlacebo234235 Characteristics of all the studies included in the meta-analysis Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 15 mg Tirzepatide 1 mg/5 mg/10 mg/15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 10 mg/15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 15 mg Tirzepatide 5 mg/10 mg/15 mg Tirzepatide 10 mg/15 mg Tirzepatide 10 mg/15 mg Tirzepatide 15 mg Tirzepatide 10 mg/15 mg Quality evaluation and risk of bias The evaluation results of study quality are shown in Supplementary Fig. 1 and Supplementary Fig. 2. All studies underwent evaluation using the CCRBT and met the requirements for meta-analysis. Among the 20 included RCTs, 10 were judged to have a low overall risk of bias, 8 an unclear risk, and 2 a high risk. Due to the lack of blinding for outcome assessors, one study was deemed to have a high risk of bias in outcome assessment. Additionally, one study was identified as having a high risk of bias due to incomplete outcome data. Overall, most studies were assessed as low risk, and all studies were considered to be of high quality. Analysis of main outcome These 20 studies explored the relation between tirzepatide intervention and adverse cardiovascular events or renal adverse events. Pooled results showed no significant differences was observed between the tirzepatide group and the control group in adverse cardiovascular events (RR = 0.83, 95%CI: 0.63–1.08, p = 0.16, I²=0%; Fig. 2) and renal events (RR = 1.22, 95%CI: 0.78–1.89, p = 0.39, I²=0%; Fig. 3). Additionally, funnel plots demonstrated approximate symmetry, suggesting no significant publication bias was observed (Figs. 4 and 5). Sensitivity analysis showed that the results remain stable after one-by-one exclusion. Fig. 2Forest plot depicting the relation between tirzepatide and adverse cardiovascular events in participants with T2DM or obesity Forest plot depicting the relation between tirzepatide and adverse cardiovascular events in participants with T2DM or obesity Fig. 3Forest plot depicting the relation between tirzepatide and renal outcomes in participants with T2DM or obesity Forest plot depicting the relation between tirzepatide and renal outcomes in participants with T2DM or obesity Fig. 4Funnel plot assessing publication bias of adverse cardiovascular events in the meta-analysis Funnel plot assessing publication bias of adverse cardiovascular events in the meta-analysis Fig. 5Funnel plot assessing publication bias of renal outcomes in the meta-analysis Funnel plot assessing publication bias of renal outcomes in the meta-analysis Subgroup analysis For adverse cardiovascular events, participants were categorized into T2DM patients and obese subjects according to their indications. Statistical analysis revealed no significant difference in adverse cardiovascular events incidence between the two groups: T2DM patients (RR = 0.85, p = 0.25) and obese subjects (RR = 0.61, p = 0.29). Adverse cardiovascular events were further subclassified into MI, coronary artery disease (CAD), HF, and stroke. Subgroup analysis revealed no significant differences between groups in any adverse cardiovascular events components (MI: RR = 0.75, p = 0.21; CAD: RR = 0.69, p = 0.17; HF: RR = 0.62, p = 0.11; stroke: RR = 1.21, p = 0.48). Based on tirzepatide dosage, participants were divided into 5 mg, 10 mg, and 15 mg subgroups. No significant differences were observed between the intervention and control groups across all doses (5 mg: RR = 1.08, p = 0.67; 10 mg: RR = 0.78, p = 0.19; 15 mg: RR = 0.81, p = 0.29). Furthermore, when grouped by the type of comparator, no significant differences were found between the two groups (GLP-1 RAs: RR = 1.21, p = 0.66; Insulin: RR = 0.82, p = 0.20; Placebo: RR = 0.65, p = 0.16). Detailed breakdown is available in Table 2. Table 2Subgroup analysis of the relation between Tirzepatide and adverse cardiovascular events in participants with T2DM or obesitySubgroupNo. of studiesNo. of eventsRR95%CI p I2 (%)ExposureControlType of disease T2DM13109940.85[0.64, 1.12]0.250 Obesity71090.61[0.24, 1.54]0.290Type of adverse cardiovascular events Myocardial infarction1638360.75[0.49, 1.17]0.210 T2DM1135330.76[0.47, 1.21]0.250 Obesity5330.72[0.21, 2.45]0.590 Coronary artery disease1326280.69[0.41, 1.16]0.170 T2DM1025260.73[0.43, 1.25]0.250 Heart failure1118180.62[0.34, 1.11]0.110 T2DM918160.69[0.37, 1.28]0.240 Stroke1037191.21[0.71, 2.08]0.480 T2DM731171.23[0.68, 2.19]0.490 Obesity3621.15[0.27, 4.90]0.850Dose of Tirzepatide 5 mg1147921.08[0.76, 1.54]0.670 10 mg1235960.78[0.53, 1.13]0.190 15 mg1236920.81[0.54, 1.20]0.290Type of comparator GLP-1 RAs62471.21[0.52, 2.81]0.660 Insulin371790.82[0.60, 1.12]0.200 Placebo1325170.65[0.35, 1.19]0.160 Table 2Subgroup analysis of the relation between Tirzepatide and adverse cardiovascular events in participants with T2DM or obesitySubgroupNo. of studiesNo. of eventsRR95%CI p I2 (%)ExposureControlType of disease T2DM13109940.85[0.64, 1.12]0.250 Obesity71090.61[0.24, 1.54]0.290Type of adverse cardiovascular events Myocardial infarction1638360.75[0.49, 1.17]0.210 T2DM1135330.76[0.47, 1.21]0.250 Obesity5330.72[0.21, 2.45]0.590 Coronary artery disease1326280.69[0.41, 1.16]0.170 T2DM1025260.73[0.43, 1.25]0.250 Heart failure1118180.62[0.34, 1.11]0.110 T2DM918160.69[0.37, 1.28]0.240 Stroke1037191.21[0.71, 2.08]0.480 T2DM731171.23[0.68, 2.19]0.490 Obesity3621.15[0.27, 4.90]0.850Dose of Tirzepatide 5 mg1147921.08[0.76, 1.54]0.670 10 mg1235960.78[0.53, 1.13]0.190 15 mg1236920.81[0.54, 1.20]0.290Type of comparator GLP-1 RAs62471.21[0.52, 2.81]0.660 Insulin371790.82[0.60, 1.12]0.200 Placebo1325170.65[0.35, 1.19]0.160 Subgroup analysis of the relation between Tirzepatide and adverse cardiovascular events in participants with T2DM or obesity Regarding renal adverse events, participants were similarly classified into T2DM patients and obese subjects. Statistical analysis showed no significant difference in renal adverse event incidence between the two groups: T2DM patients (RR = 1.43, p = 0.22) and obese subjects (RR = 0.93, p = 0.83). Renal adverse events were categorized into UTI, nephrolithiasis, KI, and renal cell carcinoma. No significant differences were observed between groups in any renal adverse event subtype (KI: RR = 1.01, p = 0.98; nephrolithiasis: RR = 1.15, p = 0.76; UTI: RR = 0.91, p = 0.76; renal cell carcinoma: RR = 1.18, p = 0.76). In the tirzepatide dosage subgroup, no significant differences were found between groups at 5 mg, 10 mg and 15 mg doses (5 mg: RR = 1.65, p = 0.14; 10 mg: RR = 1.54, p = 0.10; 15 mg: RR = 1.22, p = 0.51). Additionally, when grouped by the type of comparator, no significant differences were found between the two groups (GLP-1 RAs: RR = 1.37, p = 0.55; Insulin: RR = 0.66, p = 0.32; Placebo: RR = 1.68, p = 0.11). Further details are provided in Table 3. Table 3Subgroup analysis of the relation between Tirzepatide and renal outcomes in participants with T2DM or obesitySubgroupNo. of studiesNo. of eventsRR95%CI p I2 (%)ExposureControlType of disease T2DM1040141.43[0.81, 2.55]0.2213 Obesity617130.93[0.46, 1.87]0.830Type of renal outcomes Kidney injury111791.01[0.51, 1.99]0.980 T2DM71180.82[0.37, 1.81]0.630 Obesity4611.76[0.44, 7.05]0.430 Nephrolithiasis91341.15[0.47, 2.82]0.760 T2DM61011.50[0.44, 5.11]0.510 Obesity3330.80[0.21, 3.10]0.7526 Urinary tract infection1221130.91[0.49, 1.69]0.760 T2DM71551.21[0.53, 2.78]0.6529 Obesity5680.60[0.23, 1.60]0.310 Renal cell carcinoma7611.18[0.41, 3.35]0.760 T2DM4401.37[0.29, 6.50]0.690 Obesity3211.01[0.25, 4.16]0.9926Dose of Tirzepatide 5 mg1015151.65[0.86, 3.19]0.140 10 mg1530261.54[0.92, 2.58]0.108 15 mg1416201.22[0.68, 2.19]0.510Type of comparator GLP-1 RAs41931.37[0.49, 3.83]0.5542 Insulin311140.66[0.29, 1.50]0.320 Placebo1137101.68[0.89, 3.17]0.110 Table 3Subgroup analysis of the relation between Tirzepatide and renal outcomes in participants with T2DM or obesitySubgroupNo. of studiesNo. of eventsRR95%CI p I2 (%)ExposureControlType of disease T2DM1040141.43[0.81, 2.55]0.2213 Obesity617130.93[0.46, 1.87]0.830Type of renal outcomes Kidney injury111791.01[0.51, 1.99]0.980 T2DM71180.82[0.37, 1.81]0.630 Obesity4611.76[0.44, 7.05]0.430 Nephrolithiasis91341.15[0.47, 2.82]0.760 T2DM61011.50[0.44, 5.11]0.510 Obesity3330.80[0.21, 3.10]0.7526 Urinary tract infection1221130.91[0.49, 1.69]0.760 T2DM71551.21[0.53, 2.78]0.6529 Obesity5680.60[0.23, 1.60]0.310 Renal cell carcinoma7611.18[0.41, 3.35]0.760 T2DM4401.37[0.29, 6.50]0.690 Obesity3211.01[0.25, 4.16]0.9926Dose of Tirzepatide 5 mg1015151.65[0.86, 3.19]0.140 10 mg1530261.54[0.92, 2.58]0.108 15 mg1416201.22[0.68, 2.19]0.510Type of comparator GLP-1 RAs41931.37[0.49, 3.83]0.5542 Insulin311140.66[0.29, 1.50]0.320 Placebo1137101.68[0.89, 3.17]0.110 Subgroup analysis of the relation between Tirzepatide and renal outcomes in participants with T2DM or obesity Discussion This study synthesized evidence from 20 RCTs to systematically evaluate the potential relation between tirzepatide exposure and adverse cardiovascular or renal events in participants with T2DM or obesity without HF. It was important to note that the ascertainment of cardiorenal events relied on investigator-reported adverse events, so differences in outcome definitions across the included trials could introduce a risk of misclassification. Both T2DM and obesity are established risk factors for adverse cardiovascular and renal events [36, 37]. In T2DM, chronic hyperglycemia and glycemic variability induce oxidative stress and inflammation, leading to endothelial injury [38]. This primarily drives the development of macrovascular complications, such as CAD due to atherosclerosis, as well as microvascular complications, including DKD resulting from basement membrane thickening. In obesity, altered lipid metabolism increases insulin resistance and promotes fatty acid release, further contributing to the progression of cardiovascular and renal diseases [39]. Emerging glucose-lowering agents, such as SGLT-2i and GLP-1 RAs, are widely used in clinical practice and have demonstrated cardiovascular and renal benefits. SGLT-2i and GLP-1 RAs theoretically reduce complications in T2DM and obesity through glycemic and weight control. Extensive studies have confirmed that they also attenuate the progression and mortality of cardiovascular and renal diseases through other pathways [40]. For instance, SGLT-2i reduce cardiovascular stress by improving cardiac energy metabolism, reducing inflammation, enhancing erythropoiesis [41], and inhibiting cardiac fibrosis and remodeling, thereby lowering the incidence of HF. Additionally, GLP-1 RAs have been shown to slow the decline in estimated glomerular filtration rate (eGFR) and the progression of albuminuria, providing significant renal benefits for patients with T2DM and CKD, reducing the risk of composite renal endpoints by 24% on top of standard care [42]. However, treatment-related risks associated with SGLT-2i and GLP-1 RAs cannot be overlooked. SGLT-2i increase urinary glucose excretion, elevating the risk of UTI, dehydration, orthostatic hypotension, and potentially diabetic ketoacidosis and transient serum creatinine elevation, which may lead to renal impairment [43]. GLP-1 RAs have also raised safety concerns, with some studies suggesting an increased risk of kidney stones, ureteral stones, and interstitial nephritis [44]. As a novel dual GIP and GLP-1 receptor agonist, tirzepatide is highly anticipated to possess potentially superior cardiovascular and renal effects compared to SGLT-2i and GLP-1 RAs. First, as a treatment for T2DM and obesity, tirzepatide improves metabolic risk factors (e.g., blood glucose, body weight, blood pressure), thereby reducing the risk of adverse cardiovascular and renal events. Preclinical evidence suggests that tirzepatide may confer cardiovascular protection by modulating branched-chain amino acid (BCAA) metabolism, reducing myocardial hypoxia, inflammation, and fibrosis, thereby improving cardiac remodeling [45]. Similarly, clinical studies indicate that tirzepatide promotes lipolysis, enhances fat oxidation, reduces triglycerides and low-density lipoprotein cholesterol, and favorably influences lipid profiles, all of which may contribute to cardiovascular and renal protection [46]. The SUMMIT trial, which included patients with HF with preserved ejection fraction (HFpEF) and obesity, demonstrated that tirzepatide significantly reduced the risk of cardiovascular death and HF worsening (HR = 0.62) [12]. The study population had a higher baseline risk. One study indicates that 28% of HFpEF patients experience rehospitalization due to recurrent HF [47]. Obesity and T2DM further promote HFpEF recurrence through inflammation-driven extracellular matrix remodeling. Thus, patients with HFpEF and comorbid obesity or T2DM have a substantially higher probability of HF recurrence. Under these conditions, the benefits of tirzepatide in reducing cardiovascular death and HF worsening may be more pronounced. Currently, cardiovascular outcome trials of GLP-1 RAs in T2DM patients have shown a mild protective effect against HF hospitalization risk [48], and a meta-analysis reported an 10% reduction in HF hospitalization risk [49]. However, our study population lacked a history of HF, and only one included study potentially involved participants at high cardiovascular risk [19]. Studies have shown that the incidence of HF in T2DM patients over a median follow-up of 6 years is approximately 3% [50]. Therefore, the consistently negative results across all subgroups (indication, subtype of adverse cardiovascular events, tirzepatide dose) regarding tirzepatide and adverse cardiovascular events may be attributed to the low observed incidence of adverse cardiovascular events and the relatively short median follow-up duration. Additionally, some comparator groups included GLP-1 RAs (e.g., dulaglutide, semaglutide). Given the established cardiovascular benefits of GLP-1 RAs in T2DM, this may have attenuated the comparative assessment of tirzepatide’s cardiovascular effects. Coupled with the generally short follow-up durations of the included studies, the observation of adverse cardiovascular events in the tirzepatide group was further limited, hindering a robust evaluation of tirzepatide’s cardiovascular impact in T2DM and obese populations. Regarding adverse cardiovascular events, a meta-analysis suggested that exposure to GLP-1 RAs and GIP/GLP-1 RAs was associated with a significant reduction in adverse cardiovascular events (OR = 0.87), but this composite effect was primarily driven by GLP-1 RAs, with no significant difference observed between groups [51]. Recent meta-analyses have provided valuable insights into the renal effects of tirzepatide. For instance, Kamrul-Hasan et al. and Karakasis et al. synthesized data from RCTs and concluded that tirzepatide exposure was associated with significant reductions in urinary albumin-to-creatinine ratio (UACR) (MD = −26.9% and MD = −28.7%) and proteinuria (MD = −18.03%) compared with control groups [13, 14]. Besides, prior study also reported that no significant relation was observed between tirzepatide and renal events [13]. However, our study distinguishes itself from these prior syntheses by shifting the focus from UACR and proteinuria to cardiorenal event endpoints. Furthermore, our analysis included more detailed subgroup (e.g., by indication, event subtype, dose, and comparator) to evaluate the relation between tirzepatide and cardiorenal events. Based on the incorporated data, analysis of the tirzepatide dose subgroup did not demonstrate a significant relation with the risk of adverse renal events. This suggests that tirzepatide may exert both protective and potentially harmful renal effects. The protective mechanism is supported by an exploratory analysis of the SURPASS-4 trial, which demonstrated that tirzepatide delayed eGFR decline and reduced proteinuria, potentially mediated by decreased intraglomerular pressure, suppressed inflammation, and improved metabolic parameters (e.g., glycemic/weight control) [52]. Conversely, potential risk mechanisms include tirzepatide’s osmotic diuretic effect, which may induce dehydration and transient renal impairment, as well as weight loss-related adipose tissue breakdown, which could increase the risk of uric acid crystallization [53]. Notably, the SUMMIT trial, which used cystatin C to correct creatinine bias, found a transient decline in eGFR at 12 weeks with tirzepatide but significant improvement by week 52 [54]. In summary, at different doses, the protective and potential injurious mechanisms of tirzepatide may counterbalance each other [55, 56]. This study represents the first comprehensive assessment of the cardiorenal safety of tirzepatide in T2DM or obese populations, with low heterogeneity among results enhancing the reliability of the conclusions. Although the statistical heterogeneity was low, we acknowledge the potential for clinical and methodological heterogeneity. Clinical heterogeneity may arise from differences in participant characteristics, such as the presence of comorbidities (e.g., hypertension, dyslipidemia, non-alcoholic fatty liver disease, gout) and variations in disease duration and severity. Methodological heterogeneity could stem from variations in study design, including the definition of cardiovascular and renal events. However, the consistent results and the low statistical heterogeneity suggest that our study provides relatively reliable conclusions. Moreover, several limitations warrant stronger emphasis. First, the included RCTs primarily focused on short-term efficacy with relatively brief follow-up periods. This is insufficient to fully capture the long-term incidence and progression of adverse cardiovascular and renal events, which often develop over extended periods. Second, the ascertainment of cardiorenal events presents a significant limitation. Our analysis relied on counts of adverse events, and the diagnostic criteria for cardiorenal events may have varied across studies, potentially leading to underreporting or misclassification. Besides, we could not assess the severity or outcome of these events, which is critical for a comprehensive safety evaluation. Third, although pooling multiple RCTs increased the overall sample size, the absolute number of cardiorenal events remained limited; subgroup analyses were further challenged by smaller sample sizes and potential population heterogeneity. Therefore, future research should focus on patients with elevated baseline cardiovascular or renal risk and incorporate longer follow-up durations to comprehensively elucidate the long-term impact of tirzepatide. Conclusion In summary, no significant relation between tirzepatide exposure and adverse cardiovascular or renal events in participants with T2DM or obesity was observed. Subgroup analyses based on indication, subtype of adverse cardiovascular events, subtype of adverse renal event, dose of tirzepatide, and type of comparator also showed no significant difference between exposure group and the control group in relatively short RCTs with low event rates. Adequately powered, dedicated cardiovascular and renal outcome trials remain necessary. Supplementary Information Supplementary Material 1 Supplementary Material 1 Supplementary Material 2: Risk of bias graph used for quality evaluation in the meta-analysis Supplementary Material 2: Risk of bias graph used for quality evaluation in the meta-analysis Supplementary Material 3: Risk of bias summary for quality evaluation in the meta-analysis Supplementary Material 3: Risk of bias summary for quality evaluation in the meta-analysis Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5